Pharmaceutical CDMO Famar Group has signed an agreement to acquire MiP Pharma's sterile fill-finish site in Homburg, Germany.
This strategic move will strengthen Famar's footprint in aseptic and lyophilised fill-finish, while also increasing its high-value dosage form manufacturing capacity.
Under the terms of Famar's agreement with MiP Pharma, the former will also gain access to the 100 employees working at the site, ensuring continuity and knowledge retention.
The Homburg facility has undergone significant investment and modernisation, with new quality control and microbiology laboratories being recently installed.
“The Homburg site offers world-class sterile infrastructure, newly installed QC and microbiology laboratories, and a skilled workforce,” said Konstantinos Rengis, CEO of FAMAR Group.
“This investment aligns with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with manufacturing services of the highest standards. We are proud to welcome the Homburg team to the FAMAR family and look forward to building a strong future together”.
When this transaction closes, Famar will operate 7 facilities across Europe, enhancing its ability to serve its European customers.
Dr. Friedrich Sernetz, CEO of MiP Pharma, added: “Thanks to the investments, the Homburg facility has become an attractive site for global pharmaceutical specialists."
"With the Famar Group, we have found a buyer who will not only maintain but also further develop the site. This secures jobs and lays the foundation for future growth. At the same time, we can focus on our core competency – the marketing of our medicines – and accelerate our growth”.